Oncotelic Therapeutics Maintains $388M JV Valuation Amid Biotech Volatility

Oncotelic Therapeutics Inc. (OTCQB: OTLC) has reported that the fair value of its 45% ownership stake in GMP Biotechnology Limited remained approximately $388 million in the first quarter of 2026, according to its recently filed financial results. This valuation stability comes during a period when many emerging biotechnology companies have faced significant downward pressure on their valuations due to broader market volatility.

The valuation was supported by an independent ASC 820 Level 3 assessment, which utilized discounted cash flow analysis and market comparables. This approach reinforces Oncotelic's partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures. The company's strategy contrasts with many biotech firms that rely heavily on capital raises and often experience persistent cash burn.

Oncotelic's ability to maintain its stake value highlights the potential of its pipeline and collaborative approach. The company's model aims to mitigate financial risks while pursuing high-value oncology treatments. Investor interest in platform-driven biotechnology companies, such as Northwest Biotherapeutics (OTC: NWBO), CytoDyn (OTC: DYDY), Sangamo Therapeutics (OTC: SGMO), and Insilico Medicine (OTC: ISLMF)—which recently completed a large IPO—underscores the market's focus on innovative biotech platforms.

The sustained valuation of Oncotelic's joint venture stake provides a foundation for the company's future development and potential growth. For more details, refer to the full financial results and additional information available in the company’s newsroom at https://nnw.fm/OTLC.